Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Brisbane biotech firm Ellume puts Australian arm into administration

Ellume rose to prominence last year when it announced a $300 million deal to provide COVID-19 home test kits to the US Department of Defense.

ABC News

Michael Hiltzik: In blow to public health, judge tosses FDA lawsuit targeting a clinic offering unproven stem cell treatments

A federal judge in Riverside, California, declared a stem cell treatment firm operating in the state to be exempt from Food and Drug Administration regulations, opening the door to the further proliferation of clinics offering therapies the FDA says are scientifically unproven and potentially dangerous.

Los Angeles Times

Nasdaq-listed Bright Minds Closes $4 Million Offering And Begins Dosing In Clinical Trial For Epilepsy

Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Approves Updated COVID-19 Booster Shots

But does everyone really need to get boosted?

Reason

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Benzinga

US approves shots targeting Omicron

Washington (AFP) - US officials Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, hoping to contain a new wave of feared contagions this winter.

AFP

How IBD Stock Of The Day Neurocrine Bio Shrugged Off A High-Profile Failure

Neurocrine is shrugging off market woes, buoyed by movement drug Ingrezza and NBIX stock investors' hope for its pipeline.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

US approves updated Pfizer, Moderna shots targeting Omicron

Washington (AFP) - US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.

AFP

FDA clears way for boosters targeted at latest COVID variants

COVID-19 boosters from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE that are tailored to the latest COVID-19 omicron variants got U.S. regulatory clearance, a move toward additional protection as concern grows about potential new waves in the fall and winter.

Tribune News Service

Will Updated Covid Boosters Save Pfizer, Moderna? The Stocks Say No

Vaccine makers' stocks sank Wednesday despite Food and Drug Administration authorization for their updated Covid booster shots.

Investors Business Daily

US clears updated Covid boosters targeting the newest Omicron strain

Omicron booster shots could become available within days

The Independent UK

FDA authorizes Omicron boosters

The updated shots are expected to become available after Labor Day.

Axios

US clears updated COVID boosters targeting newest variants

U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain

The Independent UK

Editorial: Extend, fund free COVID tests

The COVID-19 virus's course and evolution remain unpredictable. But this far into the pandemic, there are some safe assumptions.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression

Cybin Inc.

Tribune News Service

FDA to approve new omicron COVID-19 boosters

The Food and Drug Administration is set to approve new boosters that specifically target the omicron mutation of COVID-19.

StockNews.com

2 Stocks That Are More Than COVID-19 Plays

While the COVID-19 pandemic benefitted Johnson & Johnson (JNJ) and Pfizer (PFE) significantly as their vaccines helped the world recover from the crisis, these stocks are more than just COVID-19 plays because of their strong product portfolio and pipeline. They are well-positioned to capitalize on the rising chronic diseases, an…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Competitive drug prices are great for consumers. Turns out, they're good for industry, too.

The Independent UK

FDA chief says long-awaited opioid review still in the works

The head of the Food and Drug Administration says a government review of prescription opioid medications, including their risks and contribution to the U.S. overdose epidemic, is still underway

Birmingham Post

Pharmaceuticals giant acquires California counterpart for £221.5m

Med-Pharmex employs around 130 people

Investors Business Daily

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

The Street

Bristol Myers Stock Slumps After Mixed Data From Stroke Drug Trial

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

The Street

Bristol Myers

Benzinga

Khiron Q2 Revenue Grows 60% YoY, Despite Decline In Medical Cannabis Sales In Germany

Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX: KHRNF) (Frankfurt:A2JMZC) Q2 2022 total revenue was CA$4.5 million ($3.45 million), up 60% year-over-year, driven by growth in the medical cannabis segment in Colombia and the United Kingdom.

1 … 131 132 133 134

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Department of Defense

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.